Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$7.93

 0.07 (0.89%)

High$8.17
Low$7.83
Volume148,209
Market Cap$111,865,980

07/19/18  1:15 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $7.93 with a 52 week high of $21.59 and a 52 week low of $4.75.

Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients

06/28/18

Read More

Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD

05/18/18

Read More

Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

05/08/18

Read More


There are currently no events scheduled.